ZBIO — Zenas BioPharma, Inc. stock price, charts and financials

Latest market price

32.16

-0.27-0.83%

Overview Short InterestFilings

ZBIOQT87Zenas BioPharma, Inc.·NASDAQ

Overview Short InterestFilings

32.16-0.83%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

MESO+4.71%$16.69 AUPH-2.45%$15.46 GHRS-1.62%$29.78 OCUL-0.05%$9.19 TSHA-1.51%$6.46 STOK-1.22%$32.31 ABCL+39.97%$9.70 VRDN-3.29%$22.81

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	25.59%	Shs Outstand	63.13M	Perf Week	3.15%

Market Cap	2.05B	Forward P/E	-	EPS next Y	-4.77	Insider Trans	2.78%	Shs Float	14.80M	Perf Month	10.19%

Enterprise Value	1.90B	PEG	0.04	EPS next Q	-	Inst Own	-	Short Float	82.23%	Perf Quarter	68.29%

Income	-482.58M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	16.78	Perf Half Y	54.36%

Sales	10.00M	P/B	5.37	EPS next Y	0.90%	ROA	-56.86%	Short Interest	12.17M	Perf YTD	-10.69%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-167.71%	52W High	44.23 -27.29%	Perf Year	106.56%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-61.53%	52W Low	13.39 140.22%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	4.67% 6.23%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-33.78%	Oper. Margin	0.00%	ATR (14)	1.81	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	11.94	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	63.36	Recom	2.20

Dividend Gr. 3/5Y	-	Current Ratio	11.94	EPS Q/Q	-82.50%	SMA20	4.83%	Beta	0.91	Target Price	22.00

Payout	0.00%	Debt/Eq	1.05	Sales Q/Q	-100.00%	SMA50	27.52%	Rel Volume	0.34	Prev Close	32.43

Employees	167	LT Debt/Eq	0.33	Earnings	Aug 11	SMA200	25.24%	Avg Volume	782.83K	Price	32.16

IPO Date	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.96% -	Net Debt/EBITDA	0.36	Volume	264,044	Change	-0.83%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-14-26	Reiterated	Morgan Stanley	Equal Weight	$19 → $22
Jan-06-26	Reiterated	Jefferies		$52 → $48
Jan-06-26	Downgrade	Morgan Stanley	Overweight → Equal Weight	$19
Oct-28-25	Reiterated	HC Wainwright & Co.	Buy	$44
Oct-27-25	Reiterated	Jefferies		$35 → $52
Oct-08-24	Initiated	Jefferies	Buy	$35

Latest News

Jul-28-26

Jul-28-2601:15AM

Financial Review: Arcturus Therapeutics (NASDAQ:ARCT) vs. Zenas BioPharma (NASDAQ:ZBIO)defenseworld.net

Jul-17-26

Jul-17-2604:15PM

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Jul-14-26

Jul-14-2608:47AM

Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchiseseekingalpha.com

Jun-12-26

Jun-12-2608:02AM

Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market SessionBenzinga

Company

Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022
Total Revenue	10	5	50	—
Cost of Goods Sold Incl. D&A	0	139	0	—
Gross Profit	10	-134	50	—
Selling, General and Administrative Excl. Other	53	30	17	—
Research and Development	168	139	60	—
Other Operating Expense	0	-139	10	—
Operating Income	-211	-164	-37	—
Interest Expense	7	0	0	—
Unusual Expense	—	—	—	—
Non-Operating Income (Expense)	-159	7	0	—
Net Income Before Taxes	-378	-157	-37	—
Income Taxes	0	0	0	—
Consolidated Net Income	-378	-157	-37	—
Net Income From Continuing Operations	-378	-157	-37	—
Net Income	-378	-157	-37	—
EPS (Recurring)	-8.44	-3.76	-0.97	—
EPS (Basic, Before Extraordinaries)	-8.44	-3.76	-0.97	—
EPS (Diluted)	-8.44	-3.76	-0.97	—
EBITDA	-370	-156	-27	—
Other After Tax Adjustments	—	—	—	—
Stock Option Compensation Expense	—	—	—	—
Price To Earnings Ratio	—	—	—	—
Price To Sales Ratio	163.40	68.80	—	—
Gross Margin	100.00	-2,680.00	100.00	—
Operating Margin	-2,110.00	-3,280.00	-74.00	—
Net Margin	-3,780.00	-3,140.00	-74.00	—
Shares Outstanding	45	42	38	—
Market Capitalization	1,634	344	—	—
Operating Lease Expense	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOULDER LEON O JR	Chief Executive Officer	May 18 '26	Buy	16.88	60,000	1,012,800	96,928	May 18
MOULDER LEON O JR	Chief Executive Officer	Apr 29 '26	Buy	17.62	35,000	616,700	1,786,039	Apr 29
MOULDER LEON O JR	Chief Executive Officer	Apr 28 '26	Buy	18.02	25,000	450,500	1,751,039	Apr 29
Lu Hongbo	Director	Mar 31 '26	Buy	19.93	78,768	1,570,198	426,736	Apr 02
Fairmount Funds Management LLC	Director	Mar 31 '26	Buy	20.00	150,000	3,000,000	2,359,025	Apr 01
MOULDER LEON O JR	Chief Executive Officer	Mar 31 '26	Buy	19.31	34,000	656,540	1,726,039	Mar 31
MOULDER LEON O JR	Chief Executive Officer	Mar 30 '26	Buy	18.23	20,000	364,600	1,692,039	Mar 31
Allen Patricia L	Director	Feb 13 '26	Buy	26.36	4,160	109,658	19,860	Feb 13
Allen Patricia L	Director	Feb 12 '26	Buy	24.85	15,700	390,088	15,700	Feb 13
Lu Hongbo	Director	Feb 11 '26	Buy	22.50	25,985	584,663	347,968	Feb 13
MOULDER LEON O JR	Chief Executive Officer	Feb 02 '26	Buy	17.96	57,000	1,023,720	423,155	Feb 03
MOULDER LEON O JR	Chief Executive Officer	Jan 09 '26	Buy	16.55	20,000	331,000	366,155	Jan 09
MOULDER LEON O JR	Chief Executive Officer	Jan 08 '26	Buy	16.30	30,000	489,000	346,155	Jan 09
MOULDER LEON O JR	Chief Executive Officer	Jan 07 '26	Buy	16.38	50,000	819,000	316,155	Jan 09
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Oct 09 '25	Buy	19.00	126,315	2,399,985	1,917,895	Oct 14

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.